1
|
Bochenek MA, Walters B, Zhang J, Fenton OS, Facklam A, Kroneková Z, Pelach M, Engquist EN, Leite NC, Morgart A, Lacík I, Langer R, Anderson DG. Enhancing the Functionality of Immunoisolated Human SC-βeta Cell Clusters through Prior Resizing. Small 2024:e2307464. [PMID: 38212275 DOI: 10.1002/smll.202307464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/27/2023] [Revised: 12/10/2023] [Indexed: 01/13/2024]
Abstract
The transplantation of immunoisolated stem cell derived beta cell clusters (SC-β) has the potential to restore physiological glycemic control in patients with type I diabetes. This strategy is attractive as it uses a renewable β-cell source without the need for systemic immune suppression. SC-β cells have been shown to reverse diabetes in immune compromised mice when transplanted as ≈300 µm diameter clusters into sites where they can become revascularized. However, immunoisolated SC-β clusters are not directly revascularized and rely on slower diffusion of nutrients through a membrane. It is hypothesized that smaller SC-β cell clusters (≈150 µm diameter), more similar to islets, will perform better within immunoisolation devices due to enhanced mass transport. To test this, SC-β cells are resized into small clusters, encapsulated in alginate spheres, and coated with a biocompatible A10 polycation coating that resists fibrosis. After transplantation into diabetic immune competent C57BL/6 mice, the "resized" SC-β cells plus the A10 biocompatible polycation coating induced long-term euglycemia in the mice (6 months). After retrieval, the resized A10 SC-β cells exhibited the least amount of fibrosis and enhanced markers of β-cell maturation. The utilization of small SC-β cell clusters within immunoprotection devices may improve clinical translation in the future.
Collapse
Affiliation(s)
- Matthew A Bochenek
- David H Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 500 Main Street, Cambridge, MA, 02139, USA
- Department of Chemical Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139, USA
- Department of Anesthesiology, Boston Children's Hospital, 300 Longwood Ave, Boston, MA, 02115, USA
| | - Ben Walters
- David H Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 500 Main Street, Cambridge, MA, 02139, USA
- Department of Chemical Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139, USA
- Department of Anesthesiology, Boston Children's Hospital, 300 Longwood Ave, Boston, MA, 02115, USA
| | - Jingping Zhang
- Harvard University, 7 Divinity Avenue, Cambridge, MA, 02138, USA
| | - Owen S Fenton
- David H Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 500 Main Street, Cambridge, MA, 02139, USA
- Department of Chemical Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139, USA
| | - Amanda Facklam
- David H Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 500 Main Street, Cambridge, MA, 02139, USA
- Department of Biological Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139, USA
| | - Zuzana Kroneková
- Department for Biomaterials Research, Polymer Institute of the Slovak Academy of Sciences, Dubravska cesta 9, Bratislava, 845 41, Slovakia
| | - Michal Pelach
- Department for Biomaterials Research, Polymer Institute of the Slovak Academy of Sciences, Dubravska cesta 9, Bratislava, 845 41, Slovakia
| | - Elise N Engquist
- Harvard University, 7 Divinity Avenue, Cambridge, MA, 02138, USA
| | - Nayara C Leite
- Harvard University, 7 Divinity Avenue, Cambridge, MA, 02138, USA
| | - Alex Morgart
- David H Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 500 Main Street, Cambridge, MA, 02139, USA
- Department of Chemical Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139, USA
- Department of Anesthesiology, Boston Children's Hospital, 300 Longwood Ave, Boston, MA, 02115, USA
| | - Igor Lacík
- Department for Biomaterials Research, Polymer Institute of the Slovak Academy of Sciences, Dubravska cesta 9, Bratislava, 845 41, Slovakia
| | - Robert Langer
- David H Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 500 Main Street, Cambridge, MA, 02139, USA
- Department of Chemical Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139, USA
- Department of Anesthesiology, Boston Children's Hospital, 300 Longwood Ave, Boston, MA, 02115, USA
- Division of Health Science Technology, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139, USA
- Institute for Medical Engineering and Science, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139, USA
| | - Daniel G Anderson
- David H Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 500 Main Street, Cambridge, MA, 02139, USA
- Department of Chemical Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139, USA
- Department of Anesthesiology, Boston Children's Hospital, 300 Longwood Ave, Boston, MA, 02115, USA
- Division of Health Science Technology, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139, USA
- Institute for Medical Engineering and Science, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139, USA
| |
Collapse
|
2
|
Leite NC, Sintov E, Meissner TB, Brehm MA, Greiner DL, Harlan DM, Melton DA. Modeling Type 1 Diabetes In Vitro Using Human Pluripotent Stem Cells. Cell Rep 2021; 32:107894. [PMID: 32668238 PMCID: PMC7359783 DOI: 10.1016/j.celrep.2020.107894] [Citation(s) in RCA: 46] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2020] [Revised: 05/01/2020] [Accepted: 06/21/2020] [Indexed: 01/01/2023] Open
Abstract
Understanding the root causes of autoimmune diseases is hampered by the inability to access relevant human tissues and identify the time of disease onset. To examine the interaction of immune cells and their cellular targets in type 1 diabetes, we differentiated human induced pluripotent stem cells into pancreatic endocrine cells, including β cells. Here, we describe an in vitro platform that models features of human type 1 diabetes using stress-induced patient-derived endocrine cells and autologous immune cells. We demonstrate a cell-type-specific response by autologous immune cells against induced pluripotent stem cell-derived β cells, along with a reduced effect on α cells. This approach represents a path to developing disease models that use patient-derived cells to predict the outcome of an autoimmune response.
Collapse
Affiliation(s)
- Nayara C Leite
- Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA
| | - Elad Sintov
- Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA.
| | - Torsten B Meissner
- Department of Surgery, Beth Israel Deaconess Medical Center, Boston, 02215 MA, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
| | - Michael A Brehm
- Program in Molecular Medicine, Diabetes Center of Excellence, University of Massachusetts Medical School, Worcester, MA 01655, USA
| | - Dale L Greiner
- Program in Molecular Medicine, Diabetes Center of Excellence, University of Massachusetts Medical School, Worcester, MA 01655, USA
| | - David M Harlan
- Department of Medicine, Diabetes Center of Excellence, University of Massachusetts Medical School, Worcester, MA 01655, USA
| | - Douglas A Melton
- Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
| |
Collapse
|
3
|
Huang L, Desai R, Conrad DN, Leite NC, Akshinthala D, Lim CM, Gonzalez R, Muthuswamy LB, Gartner Z, Muthuswamy SK. Commitment and oncogene-induced plasticity of human stem cell-derived pancreatic acinar and ductal organoids. Cell Stem Cell 2021; 28:1090-1104.e6. [PMID: 33915081 PMCID: PMC8202734 DOI: 10.1016/j.stem.2021.03.022] [Citation(s) in RCA: 56] [Impact Index Per Article: 18.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2020] [Revised: 02/14/2021] [Accepted: 03/29/2021] [Indexed: 02/06/2023]
Abstract
The exocrine pancreas, consisting of ducts and acini, is the site of origin of pancreatitis and pancreatic ductal adenocarcinoma (PDAC). Our understanding of the genesis and progression of human pancreatic diseases, including PDAC, is limited because of challenges in maintaining human acinar and ductal cells in culture. Here we report induction of human pluripotent stem cells toward pancreatic ductal and acinar organoids that recapitulate properties of the neonatal exocrine pancreas. Expression of the PDAC-associated oncogene GNASR201C induces cystic growth more effectively in ductal than acinar organoids, whereas KRASG12D is more effective in modeling cancer in vivo when expressed in acinar compared with ductal organoids. KRASG12D, but not GNASR201C, induces acinar-to-ductal metaplasia-like changes in culture and in vivo. We develop a renewable source of ductal and acinar organoids for modeling exocrine development and diseases and demonstrate lineage tropism and plasticity for oncogene action in the human pancreas.
Collapse
Affiliation(s)
- Ling Huang
- Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
| | - Ridhdhi Desai
- Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
| | - Daniel N Conrad
- Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA 94158, USA
| | - Nayara C Leite
- Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA
| | - Dipikaa Akshinthala
- Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
| | - Christine Maria Lim
- Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
| | - Raul Gonzalez
- Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
| | - Lakshmi B Muthuswamy
- Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
| | - Zev Gartner
- Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA 94158, USA; Chan-Zuckerberg Biohub, San Francisco, CA 94158, USA; NSF Center for Cellular Construction, San Francisco, CA 94158, USA
| | - Senthil K Muthuswamy
- Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
| |
Collapse
|
4
|
Cai EP, Ishikawa Y, Zhang W, Leite NC, Li J, Hou S, Kiaf B, Hollister-Lock J, Yilmaz NK, Schiffer CA, Melton DA, Kissler S, Yi P. Genome-scale in vivo CRISPR screen identifies RNLS as a target for beta cell protection in type 1 diabetes. Nat Metab 2020; 2:934-945. [PMID: 32719542 PMCID: PMC7502486 DOI: 10.1038/s42255-020-0254-1] [Citation(s) in RCA: 45] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/26/2020] [Accepted: 06/26/2020] [Indexed: 02/06/2023]
Abstract
Type 1 diabetes (T1D) is caused by the autoimmune destruction of pancreatic beta cells. Pluripotent stem cells can now be differentiated into beta cells, thus raising the prospect of a cell replacement therapy for T1D. However, autoimmunity would rapidly destroy newly transplanted beta cells. Using a genome-scale CRISPR screen in a mouse model for T1D, we show that deleting RNLS, a genome-wide association study candidate gene for T1D, made beta cells resistant to autoimmune killing. Structure-based modelling identified the U.S. Food and Drug Administration-approved drug pargyline as a potential RNLS inhibitor. Oral pargyline treatment protected transplanted beta cells in diabetic mice, thus leading to disease reversal. Furthermore, pargyline prevented or delayed diabetes onset in several mouse models for T1D. Our results identify RNLS as a modifier of beta cell vulnerability and as a potential therapeutic target to avert beta cell loss in T1D.
Collapse
Affiliation(s)
- Erica P Cai
- Islet Cell and Regenerative Biology, Joslin Diabetes Center, Harvard Medical School, Boston, MA, USA
| | - Yuki Ishikawa
- Section for Immunobiology, Joslin Diabetes Center, Harvard Medical School, Boston, MA, USA
| | - Wei Zhang
- Section for Immunobiology, Joslin Diabetes Center, Harvard Medical School, Boston, MA, USA
| | - Nayara C Leite
- Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, MA, USA
| | - Jian Li
- Islet Cell and Regenerative Biology, Joslin Diabetes Center, Harvard Medical School, Boston, MA, USA
| | - Shurong Hou
- Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA, USA
| | - Badr Kiaf
- Section for Immunobiology, Joslin Diabetes Center, Harvard Medical School, Boston, MA, USA
| | - Jennifer Hollister-Lock
- Islet Cell and Regenerative Biology, Joslin Diabetes Center, Harvard Medical School, Boston, MA, USA
| | - Nese Kurt Yilmaz
- Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA, USA
| | - Celia A Schiffer
- Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA, USA
| | - Douglas A Melton
- Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, MA, USA
| | - Stephan Kissler
- Section for Immunobiology, Joslin Diabetes Center, Harvard Medical School, Boston, MA, USA.
| | - Peng Yi
- Islet Cell and Regenerative Biology, Joslin Diabetes Center, Harvard Medical School, Boston, MA, USA.
| |
Collapse
|
5
|
Ferreira SM, Costa-Júnior JM, Kurauti MA, Leite NC, Ortis F, Rezende LF, Barbosa HC, Boschero AC, Santos GJ. ARHGAP21 Acts as an Inhibitor of the Glucose-Stimulated Insulin Secretion Process. Front Endocrinol (Lausanne) 2020; 11:599165. [PMID: 33324349 PMCID: PMC7726208 DOI: 10.3389/fendo.2020.599165] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/26/2020] [Accepted: 10/26/2020] [Indexed: 12/17/2022] Open
Abstract
ARHGAP21 is a RhoGAP protein implicated in the modulation of insulin secretion and energy metabolism. ARHGAP21 transient-inhibition increase glucose-stimulated insulin secretion (GSIS) in neonatal islets; however, ARHGAP21 heterozygote mice have a reduced insulin secretion. These discrepancies are not totally understood, and it might be related to functional maturation of beta cells and peripheral sensitivity. Here, we investigated the real ARHGAP21 role in the insulin secretion process using an adult mouse model of acute ARHGAP21 inhibition, induced by antisense. After ARHGAP21 knockdown induction by antisense injection in 60-day old male mice, we investigated glucose and insulin tolerance test, glucose-induced insulin secretion, glucose-induced intracellular calcium dynamics, and gene expression. Our results showed that ARHGAP21 acts negatively in the GSIS of adult islet. This effect seems to be due to the modulation of important points of insulin secretion process, such as the energy metabolism (PGC1α), Ca2+ signalization (SYTVII), granule-extrusion (SNAP25), and cell-cell interaction (CX36). Therefore, based on these finds, ARHGAP21 may be an important target in Diabetes Mellitus (DM) treatment.
Collapse
Affiliation(s)
- Sandra M. Ferreira
- Obestity and Comorbidities Research Center/Biology Institute, University State of Campinas (UNICAMP), Campinas, Brazil
| | - José M. Costa-Júnior
- Obestity and Comorbidities Research Center/Biology Institute, University State of Campinas (UNICAMP), Campinas, Brazil
| | - Mirian A. Kurauti
- Departament Physiological Sciences, University State of Maringá (UEM), Maringá, Brazil
| | - Nayara C. Leite
- Obestity and Comorbidities Research Center/Biology Institute, University State of Campinas (UNICAMP), Campinas, Brazil
| | - Fernanda Ortis
- Department of Cellular Biology and Development, Institute of Biomedical Sciences, University State of São Paulo (USP), São Paulo, Brazil
| | - Luiz F. Rezende
- Departament of Physiopathology, University State of Montes Claros (UNIMONTES), Montes Claros, Brazil
| | - Helena C. Barbosa
- Obestity and Comorbidities Research Center/Biology Institute, University State of Campinas (UNICAMP), Campinas, Brazil
| | - Antonio C. Boschero
- Obestity and Comorbidities Research Center/Biology Institute, University State of Campinas (UNICAMP), Campinas, Brazil
| | - Gustavo J. Santos
- Departament of Physiological Sciences, Center for Biological Sciences, University Federal of Santa Catarina (UFSC), Florianópolis, Brazil
- *Correspondence: Gustavo J. Santos,
| |
Collapse
|
6
|
Cardoso CRL, Leite NC, Moram CBM, Salles GF. Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study. Cardiovasc Diabetol 2018; 17:33. [PMID: 29477146 PMCID: PMC6389075 DOI: 10.1186/s12933-018-0677-0] [Citation(s) in RCA: 122] [Impact Index Per Article: 20.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/11/2018] [Accepted: 02/16/2018] [Indexed: 12/11/2022] Open
Abstract
Background Long-term visit-to-visit glycemic variability is an additional measure of glycemic control. We aimed to evaluate the prognostic value of several measures of glycemic variability for the occurrence of micro- and macrovascular complications, and all-cause mortality in patients with type 2 diabetes. Methods 654 individuals were followed-up over a median of 9.3 years. Glycemic variability (SDs and coefficients of variation of HbA1c and fasting glycaemia) was measured during the first 12- and 24-months. Multivariate Cox analysis, adjusted for risk factors and mean HbA1c and fasting glycaemia levels, examined the associations between glycemic variability and the occurrence of microvascular (retinopathy, microalbuminuria, renal function deterioration, peripheral neuropathy) and macrovascular complications [total cardiovascular events (CVE), major adverse CVEs (MACE) and cardiovascular mortality], and of all-cause mortality. Results During follow-up, 128 patients had a CVE (96 MACE), and 158 patients died (67 from cardiovascular diseases); 152 newly-developed or worsened diabetic retinopathy, 183 achieved the renal composite outcome (89 newly developed microalbuminuria and 91 deteriorated renal function), and 96 newly-developed or worsened peripheral neuropathy. Glycemic variability, particularly the 24-month parameters either estimated by HbA1c or by fasting glycemia, predicted all endpoints, except for retinopathy and peripheral neuropathy development/progression, and was a better predictor than mean HbA1c. Glycemic variability predicted retinopathy development/progression in patients with good glycemic control (HbA1c ≤ 7.5%, 58 mmol/mol) and predicted new-incident peripheral neuropathy. Conclusions Long-term visit-to-visit glycemic variability is an additional and frequently a better glycemic parameter than mean HbA1c levels for assessing the risk of future development of micro- and macrovascular complications in patients with type 2 diabetes.
Collapse
Affiliation(s)
- C R L Cardoso
- Department of Internal Medicine, University Hospital Clementino Fraga Filho, School of Medicine, Universidade Federal do Rio de Janeiro, Rua Croton, 72, Jacarepagua, Rio de Janeiro, RJ, CEP: 22750-240, Brazil
| | - N C Leite
- Department of Internal Medicine, University Hospital Clementino Fraga Filho, School of Medicine, Universidade Federal do Rio de Janeiro, Rua Croton, 72, Jacarepagua, Rio de Janeiro, RJ, CEP: 22750-240, Brazil
| | - C B M Moram
- Department of Occupational Therapy, University Hospital Clementino Fraga Filho, School of Medicine, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
| | - G F Salles
- Department of Internal Medicine, University Hospital Clementino Fraga Filho, School of Medicine, Universidade Federal do Rio de Janeiro, Rua Croton, 72, Jacarepagua, Rio de Janeiro, RJ, CEP: 22750-240, Brazil.
| |
Collapse
|
7
|
Paula FMM, Leite NC, Borck PC, Freitas-Dias R, Cnop M, Chacon-Mikahil MPT, Cavaglieri CR, Marchetti P, Boschero AC, Zoppi CC, Eizirik DL. Exercise training protects human and rodent β cells against endoplasmic reticulum stress and apoptosis. FASEB J 2018; 32:1524-1536. [PMID: 29133342 DOI: 10.1096/fj.201700710r] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Prolonged exercise has positive metabolic effects in obese or diabetic individuals. These effects are usually ascribed to improvements in insulin sensitivity. We evaluated whether exercise also generates circulating signals that protect human and rodent β cells against endoplasmic reticulum (ER) stress and apoptosis. For this purpose, we obtained serum from humans or mice before and after an 8 wk training period. Exposure of human islets or mouse or rat β cells to human or rodent sera, respectively, obtained from trained individuals reduced cytokine (IL-1β+IFN-γ)- or chemical ER stressor-induced β-cell ER stress and apoptosis, at least in part via activation of the transcription factor STAT3. These findings indicate that exercise training improves human and rodent β-cell survival under diabetogenic conditions and support lifestyle interventions as a protective approach for both type 1 and 2 diabetes.-Paula, F. M. M., Leite, N. C., Borck, P. C., Freitas-Dias, R., Cnop, M., Chacon-Mikahil, M. P. T., Cavaglieri, C. R., Marchetti, P., Boschero, A. C., Zoppi, C. C., Eizirik, D. L. Exercise training protects human and rodent β cells against endoplasmic reticulum stress and apoptosis.
Collapse
Affiliation(s)
- Flavia M M Paula
- Center for Diabetes Research, Université Libre de Bruxelles (ULB), Brussels, Belgium
| | - Nayara C Leite
- Department of Structural and Functional Biology, Institute of Biology, Obesity and Comorbidities Research Center, University of Campinas (UNICAMP), Campinas, Brazil
| | - Patricia C Borck
- Department of Structural and Functional Biology, Institute of Biology, Obesity and Comorbidities Research Center, University of Campinas (UNICAMP), Campinas, Brazil
| | - Ricardo Freitas-Dias
- Department of Structural and Functional Biology, Institute of Biology, Obesity and Comorbidities Research Center, University of Campinas (UNICAMP), Campinas, Brazil.,Department of Physical Therapy, University of Pernambuco, Petrolina, Brazil
| | - Miriam Cnop
- Center for Diabetes Research, Université Libre de Bruxelles (ULB), Brussels, Belgium.,Division of Endocrinology, Erasmus Hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium
| | - Mara P T Chacon-Mikahil
- Exercise Physiology Laboratory (FISEX), Faculty of Physical Education, University of Campinas (UNICAMP), Campinas, Brazil; and
| | - Claudia R Cavaglieri
- Exercise Physiology Laboratory (FISEX), Faculty of Physical Education, University of Campinas (UNICAMP), Campinas, Brazil; and
| | - Piero Marchetti
- Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - Antonio C Boschero
- Department of Structural and Functional Biology, Institute of Biology, Obesity and Comorbidities Research Center, University of Campinas (UNICAMP), Campinas, Brazil
| | - Claudio C Zoppi
- Department of Structural and Functional Biology, Institute of Biology, Obesity and Comorbidities Research Center, University of Campinas (UNICAMP), Campinas, Brazil
| | - Decio L Eizirik
- Center for Diabetes Research, Université Libre de Bruxelles (ULB), Brussels, Belgium
| |
Collapse
|
8
|
Santos RS, Batista TM, Camargo RL, Morato PN, Borck PC, Leite NC, Kurauti MA, Wanschel ACBA, Nadal Á, Clegg DJ, Carneiro EM. Lacking of estradiol reduces insulin exocytosis from pancreatic β-cells and increases hepatic insulin degradation. Steroids 2016; 114:16-24. [PMID: 27192429 DOI: 10.1016/j.steroids.2016.05.002] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/15/2016] [Revised: 04/18/2016] [Accepted: 05/11/2016] [Indexed: 01/08/2023]
Abstract
Low levels of plasma estrogens are associated with weight-gain, android fat distribution, and a high prevalence of obesity-related comorbidities such as glucose intolerance and type II diabetes. The mechanisms underlying the association between low levels of estrogens and impaired glucose homeostasis are not completely understood. To begin to test this, we used three-month-old female C57BL/6J mice that either underwent ovariectomy (OVX) or received a sham surgery (Sham), and we characterized glucose homeostasis. In a subsequent series of experiments, OVX mice received estradiol treatment (OVX+E2) or vehicle (OVX) for 6 consecutive days. As has been previously reported, lack of ovarian hormones resulted in dysregulated glucose homeostasis. To begin to explore the mechanisms by which this occurs, we characterized the impact of estrogens on insulin secretion and degradation in these mice. Insulin secretion and plasma insulin levels were lower in OVX mice. OVX mice had lower levels of pancreatic Syntaxin 1-A (Synt-1A) protein, which is involved in insulin extrusion from the pancreas. In the liver, OVX mice had higher levels of insulin-degrading enzyme (IDE) and this was associated with higher insulin clearance. Estradiol treatment improved glucose intolerance in OVX mice and restored insulin secretion, as well as normalized the protein content of pancreatic Synt-1A. The addition of estrogens to OVX mice reduced IDE protein to that of Sham mice. Our data suggest loss of ovarian estradiol following OVX led to impaired glucose homeostasis due to pancreatic β-cell dysfunction in the exocytosis of insulin, and upregulation of hepatic IDE protein content resulting in lower insulinemia, which was normalized by estradiol replacement.
Collapse
Affiliation(s)
- Roberta S Santos
- Departamento de Biologia Estrutural e Funcional, Instituto de Biologia, e Centro de Pesquisa em Obesidade e Comorbidades, Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil; Biomedical Research Department, Diabetes and Obesity Research Institute, Cedars-Sinai Medical Center, Beverly Hills, CA, United States.
| | - Thiago M Batista
- Departamento de Biologia Estrutural e Funcional, Instituto de Biologia, e Centro de Pesquisa em Obesidade e Comorbidades, Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil
| | - Rafael L Camargo
- Departamento de Biologia Estrutural e Funcional, Instituto de Biologia, e Centro de Pesquisa em Obesidade e Comorbidades, Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil
| | - Priscila N Morato
- Departamento de Biologia Estrutural e Funcional, Instituto de Biologia, e Centro de Pesquisa em Obesidade e Comorbidades, Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil
| | - Patrícia C Borck
- Departamento de Biologia Estrutural e Funcional, Instituto de Biologia, e Centro de Pesquisa em Obesidade e Comorbidades, Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil
| | - Nayara C Leite
- Departamento de Biologia Estrutural e Funcional, Instituto de Biologia, e Centro de Pesquisa em Obesidade e Comorbidades, Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil
| | - Mirian A Kurauti
- Departamento de Biologia Estrutural e Funcional, Instituto de Biologia, e Centro de Pesquisa em Obesidade e Comorbidades, Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil
| | - Amarylis C B A Wanschel
- Departamento de Biologia Estrutural e Funcional, Instituto de Biologia, e Centro de Pesquisa em Obesidade e Comorbidades, Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil
| | - Ángel Nadal
- CIBER de Diabetes y Enfermedades Metabólicas Asociadas, CIBERDEM, Universidad Miguel Hernández de Elche, Elche, Alicante, Spain
| | - Deborah J Clegg
- Biomedical Research Department, Diabetes and Obesity Research Institute, Cedars-Sinai Medical Center, Beverly Hills, CA, United States
| | - Everardo M Carneiro
- Departamento de Biologia Estrutural e Funcional, Instituto de Biologia, e Centro de Pesquisa em Obesidade e Comorbidades, Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil
| |
Collapse
|
9
|
Hocayen PDAS, Grassiolli S, Leite NC, Pochapski MT, Pereira RA, da Silva LA, Snack AL, Michel RG, Kagimura FY, da Cunha MAA, Malfatti CRM. Baccharis dracunculifolia methanol extract enhances glucose-stimulated insulin secretion in pancreatic islets of monosodium glutamate induced-obesity model rats. Pharm Biol 2016; 54:1263-1271. [PMID: 26194070 DOI: 10.3109/13880209.2015.1067232] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
CONTEXT Obesity is the main risk factor for type 2 diabetes mellitus. Secondary metabolites with biological activities and pharmacological potential have been identified in species of the Baccharis genus that are specifically distributed in the Americas. OBJECTIVE This study evaluated the effects of methanol extracts from Baccharis dracunculifolia DC. Asteraceae on metabolic parameters, satiety, and growth in monosodium glutamate (MSG) induced-obesity model rats. MATERIALS AND METHODS MSG was administered to 32 newborn rats (4 mg/g of body weight) once daily for 5 consecutive days. Four experimental groups (control, control + extract, MSG, and MSG + extract) were treated for 30 consecutive days with 400 mg/kg of B. dracunculifolia extract by gavage. Biochemical parameters, antioxidant activity, total extract phenolic content (methanolic, ethanolic, and acetone extractions), and pancreatic islets were evaluated. RESULTS High levels of phenolic compounds were identified in B. dracunculifolia extracts (methanol: 46.2 ± 0.4 mg GAE/L; acetate: 70.5 ± 0.5 mg GAE/L; and ethanol: 30.3 ± 0.21 mg GAE/L); high antioxidant activity was detected in B. dracunculifolia ethanol and methanol extracts. The concentration of serum insulin increased 30% in obese animals treated with extract solutions (1.4-2.0 µU/mL, p < 0.05). Insulin secretion in pancreatic islets was 8.3 mM glucose (58%, p < 0.05) and 16.7 mM (99.5%, p < 0.05) in rats in the MSG + extract and MSG groups, respectively. DISCUSSION AND CONCLUSION Treatment with B. dracunculifolia extracts protected pancreatic islets and prevented the irreversible cellular damage observed in animals in obesity and diabetes models.
Collapse
Affiliation(s)
- Palloma de A S Hocayen
- a Department of General Biology , Ponta Grossa State University , Ponta Grossa , Paraná , Brazil
| | - Sabrina Grassiolli
- a Department of General Biology , Ponta Grossa State University , Ponta Grossa , Paraná , Brazil
| | - Nayara C Leite
- a Department of General Biology , Ponta Grossa State University , Ponta Grossa , Paraná , Brazil
| | - Márcia T Pochapski
- a Department of General Biology , Ponta Grossa State University , Ponta Grossa , Paraná , Brazil
| | - Ricardo A Pereira
- b Department of General Biology , Midwest State University of Paraná , Guarapuava , Paraná , Brazil , and
| | - Luiz A da Silva
- b Department of General Biology , Midwest State University of Paraná , Guarapuava , Paraná , Brazil , and
| | - Andre L Snack
- b Department of General Biology , Midwest State University of Paraná , Guarapuava , Paraná , Brazil , and
| | - R Garcia Michel
- b Department of General Biology , Midwest State University of Paraná , Guarapuava , Paraná , Brazil , and
| | - Francini Y Kagimura
- c Chemical Department , Federal Technological University of Paraná , Pato Branco , PR , Brazil
| | - Mário A A da Cunha
- c Chemical Department , Federal Technological University of Paraná , Pato Branco , PR , Brazil
| | - Carlos R M Malfatti
- b Department of General Biology , Midwest State University of Paraná , Guarapuava , Paraná , Brazil , and
| |
Collapse
|
10
|
Pavelski M, Silva DM, Leite NC, Junior DA, de Sousa RS, Guérios SD, Dornbusch PT. Infrared Thermography in Dogs with Mammary Tumors and Healthy Dogs. J Vet Intern Med 2015; 29:1578-83. [PMID: 26289007 PMCID: PMC4895668 DOI: 10.1111/jvim.13597] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2014] [Revised: 05/27/2015] [Accepted: 07/21/2015] [Indexed: 12/21/2022] Open
Abstract
Background Infrared thermography is a painless, noninvasive, nonionizing diagnostic imaging exam used in human medicine as an auxiliary tool for breast cancer diagnosis in women. Hypothesis/Objectives Define thermographic mean temperatures of healthy mammary glands and compare these temperatures with those of mammary glands with tumors in dogs. Animals Fifty client‐owned female dogs were evaluated, including 20 with histopathologically confirmed mammary tumor and 30 clinically healthy (control). Methods A randomized study using infrared thermography analyzed each mammary gland of the animals from the control group and mammary glands with tumors from the tumor group, then the thermographic temperatures obtained were compared. Thermographic exam was performed in a temperature‐controlled room with a cooled thermographic camera—Flir E‐40 (Flir Systems®) Results There was significantly a higher temperature in the caudal abdominal and inguinal mammary glands than the other glands in the healthy group (P < .05). Dogs with mammary tumors had significantly higher thermographic temperature compared with unaffected glands regardless of the tumor size and the location (P < .05). Conclusions and clinical importance The technique seems to be able to assess for the presence of neoplasia within the mammary tissue in bitches. Further investigation is necessary to determine the impact of this technique when adopted clinically.
Collapse
Affiliation(s)
- M Pavelski
- Department of Veterinary Medicine, Federal University of Paraná, Curitiba, Brazil
| | - D M Silva
- Department of Veterinary Medicine, Federal University of Paraná, Curitiba, Brazil
| | - N C Leite
- Department of Veterinary Medicine, Federal University of Paraná, Curitiba, Brazil
| | - D A Junior
- Department of Veterinary Medicine, Federal University of Paraná, Curitiba, Brazil
| | - R S de Sousa
- Department of Veterinary Medicine, Federal University of Paraná, Curitiba, Brazil
| | - S D Guérios
- Department of Veterinary Medicine, Federal University of Paraná, Curitiba, Brazil
| | - P T Dornbusch
- Department of Veterinary Medicine, Federal University of Paraná, Curitiba, Brazil
| |
Collapse
|
11
|
Paula FMM, Leite NC, Vanzela EC, Kurauti MA, Freitas-Dias R, Carneiro EM, Boschero AC, Zoppi CC. Exercise increases pancreatic β-cell viability in a model of type 1 diabetes through IL-6 signaling. FASEB J 2015; 29:1805-16. [PMID: 25609426 DOI: 10.1096/fj.14-264820] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2014] [Accepted: 12/17/2014] [Indexed: 01/27/2023]
Abstract
Type 1 diabetes (T1D) is provoked by an autoimmune assault against pancreatic β cells. Exercise training enhances β-cell mass in T1D. Here, we investigated how exercise signals β cells in T1D condition. For this, we used several approaches. Wild-type and IL-6 knockout (KO) C57BL/6 mice were exercised. Afterward, islets from control and trained mice were exposed to inflammatory cytokines (IL-1β plus IFN-γ). Islets from control mice and β-cell lines (INS-1E and MIN6) were incubated with serum from control or trained mice or medium obtained from 5-aminoimidazole-4 carboxamide1-β-d-ribofuranoside (AICAR)-treated C2C12 skeletal muscle cells. Subsequently, islets and β cells were exposed to IL-1β plus IFN-γ. Proteins were assessed by immunoblotting, apoptosis was determined by DNA-binding dye propidium iodide fluorescence, and NO(•) was estimated by nitrite. Exercise reduced 25, 75, and 50% of the IL-1β plus IFN-γ-induced iNOS, nitrite, and cleaved caspase-3 content, respectively, in pancreatic islets. Serum from trained mice and medium from AICAR-treated C2C12 cells reduced β-cell death, induced by IL-1β plus IFN-γ treatment, in 15 and 38%, respectively. This effect was lost in samples treated with IL-6 inhibitor or with serum from exercised IL-6 KO mice. In conclusion, muscle contraction signals β-cell survival in T1D through IL-6.
Collapse
Affiliation(s)
- Flavia M M Paula
- *Department of Structural and Functional Biology, Institute of Biology, University of Campinas, Campinas, Brazil; and Department of Physical Therapy, Laboratory of Exercise Physiology and Genetics, University of Pernambuco, Petrolina, Brazil
| | - Nayara C Leite
- *Department of Structural and Functional Biology, Institute of Biology, University of Campinas, Campinas, Brazil; and Department of Physical Therapy, Laboratory of Exercise Physiology and Genetics, University of Pernambuco, Petrolina, Brazil
| | - Emerielle C Vanzela
- *Department of Structural and Functional Biology, Institute of Biology, University of Campinas, Campinas, Brazil; and Department of Physical Therapy, Laboratory of Exercise Physiology and Genetics, University of Pernambuco, Petrolina, Brazil
| | - Mirian A Kurauti
- *Department of Structural and Functional Biology, Institute of Biology, University of Campinas, Campinas, Brazil; and Department of Physical Therapy, Laboratory of Exercise Physiology and Genetics, University of Pernambuco, Petrolina, Brazil
| | - Ricardo Freitas-Dias
- *Department of Structural and Functional Biology, Institute of Biology, University of Campinas, Campinas, Brazil; and Department of Physical Therapy, Laboratory of Exercise Physiology and Genetics, University of Pernambuco, Petrolina, Brazil
| | - Everardo M Carneiro
- *Department of Structural and Functional Biology, Institute of Biology, University of Campinas, Campinas, Brazil; and Department of Physical Therapy, Laboratory of Exercise Physiology and Genetics, University of Pernambuco, Petrolina, Brazil
| | - Antonio C Boschero
- *Department of Structural and Functional Biology, Institute of Biology, University of Campinas, Campinas, Brazil; and Department of Physical Therapy, Laboratory of Exercise Physiology and Genetics, University of Pernambuco, Petrolina, Brazil
| | - Claudio C Zoppi
- *Department of Structural and Functional Biology, Institute of Biology, University of Campinas, Campinas, Brazil; and Department of Physical Therapy, Laboratory of Exercise Physiology and Genetics, University of Pernambuco, Petrolina, Brazil
| |
Collapse
|
12
|
Leite NC, Nogueira CM, Coelho HS, Perez R, Martins SJ, Soares JA, Junqueira PC. [Prevalence of antibodies to hepatitis C (anti HCV) in blood donors in Rio de Janeiro, Brazil. Its relation to ALT and anti HBC]. Arq Gastroenterol 1992; 29:5-11. [PMID: 1307202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
UNLABELLED We have studied 933 volunteer blood donors from May to July, 1990. After a interview and screening tests for syphilis, Chagas disease, malaria and HIV, they underwent an enzyme immunoassay for HBsAg, anti HBc and anti HCV antibodies. Alanine aminotransferase (ALT) serum levels were determined by auto analyser. Most blood donors were male with mean age of 33 years (19-65). Anti HCV prevalence was 3.1% (29 from 933 blood donors). Among anti HCV+, blood donors, 44.8% (13/29) had ALT 40 UI/L, 31% (9/29) were anti HBc+ and 17.2% (5/29) had both surrogate markers simultaneously. From 109 donors with ALT 40 UI/L, 13 (11.9%) were anti HCV+, while among 153 anti HBc+ donors, the anti HCV was 5.8%. CONCLUSIONS 1) we found a higher anti HCV prevalence among our blood donors than previous published reports from other countries; 2) our data show that surrogate assays do not adequately identify anti HCV blood donors, 41.4% of them would not have been excluded by anti HBc and ALT tests alone; 3) there were a correlation between anti HCV positivity with a sample to cutoff optical density ratio equal or greater than 4 and elevated ALT serum levels.
Collapse
Affiliation(s)
- N C Leite
- Serviço de Clínica, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro
| | | | | | | | | | | | | |
Collapse
|